{"schema_version":"secwatch.filing_event.v1","accession":"0001005286-26-000018","form_type":"8-K","ticker":"LFCR","cik":"0001005286","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2026-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:31.781852+00:00","generated_at":"2026-05-14T22:26:26.793402+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.72,"calibrated_materiality_score":0.72,"confidence":"high","headline":"Lifecore Biomedical Q1 revenue $23.2M (-34% YoY), net loss $15.0M, reaffirms FY2026 guidance","bullets":["Revenue $23.2M, down 34% from $35.2M; gross margin 19% vs 28% prior year.","Net loss $15.0M ($0.43 loss per diluted share) vs $14.8M loss year ago.","Adjusted EBITDA $1.0M, down $4.7M from $5.7M; operating expenses cut 52%.","Signed three new commercial site transfer programs in Q1; reaffirms full-year 2026 guidance.","Liquidity $38.1M (cash $20.8M, revolver $17.3M); free cash flow $3.6M."],"urls":{"canonical":"https://secwatch.observer/filing/0001005286-26-000018","json":"https://secwatch.observer/filing/0001005286-26-000018.json","markdown":"https://secwatch.observer/filing/0001005286-26-000018.md","text":"https://secwatch.observer/filing/0001005286-26-000018.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1005286/000100528626000018/0001005286-26-000018-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1005286/000100528626000018/lndc-20260506.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T22:26:26.793402+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e70c72e62532c2b355c5ac12170016a5a98baa9c","claim":"LIFECORE BIOMEDICAL, INC. DE reported first quarter ended March 31, 2026 results: revenue $23.2 million, net income $15.0 million, EPS $0.43 of loss per diluted share. Guidance reaffirmed.","evidence_excerpt":"the year,” stated Paul Josephs, President and Chief Executive Officer of Lifecore. Financial Snapshot and Recent Developments • Revenues for the first quarter of 2026 were $23.2 million , a decrease of $12.0 million, or 34%, compared to $35.2 million for the comparable prior year quarter ended February 23, 2025. • Gross profit margin for the first quarter of","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528626000018/0001005286-26-000018-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2026"},{"label":"Revenue","value":"$23.2 million"},{"label":"Net income","value":"$15.0 million"},{"label":"EPS","value":"$0.43 of loss per diluted share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}